Form 4: Ligand Pharma Director's Routine Stock Withholding

Ligand Pharmaceuticals director Martine Zimmermann had 115 shares withheld for tax purposes related to restricted stock units.

Summary

• Martine Zimmermann, a Director of Ligand Pharmaceuticals Inc. (LGND), reported a transaction on September 22, 2025.
• 115 shares of common stock were disposed of (withheld) by the issuer at a price of $170.77 per share.
• This disposition was for the payment of tax liability associated with the settlement of restricted stock units.
• Following this transaction, Ms. Zimmermann beneficially owns 4,443 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine tax withholding transaction for a director's restricted stock units, which is a neutral event with no direct positive or negative implications for the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction related to executive compensation.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Transaction, Stock, Director, Restricted Stock Units, Tax Withholding